Sign up Australia
Proactive Investors - Run By Investors For Investors

Cann Group to launch cannabis vaporizing system in Australia

Canada’s second largest listed medicinal cannabis company is a cornerstone investor in Cann.
Cann Group to launch cannabis vaporizing system in Australia
The vaporizer device accepts single-use pods containing precisely prepared ground cannabis

Cann Group Ltd (ASX:CAN) has signed up with CannaKorp, Inc. to import and sell CannaKorp’s proprietary vaporizing system and to produce the medicinal cannabis pods associated with the device.

CannaKorp is a Massachusetts-based technology start-up that is simplifying and improving the inhalation process for medicinal cannabis patients.

The company has designed and developed a vaporization technology which incorporates a desktop vaporizer device that accepts single-use pods containing precisely prepared ground cannabis.

Under the terms of the agreement, Cann has been granted a license to import and sell the system in Australia and New Zealand.

Cann has also obtained the manufacturing rights, which includes an initial nine-month exclusive right following regulatory approvals.

The vaporizing system will be available as an open platform for licensed medicinal cannabis cultivators looking to have their cannabis available via a vaporization device.

The patent-pending system has a hygienic, one-way valve mouthpiece that is detachable for convenient cleaning.

A microprocessor controls the system to ensure optimal performance including temperature, time and air pressure.

The pod system will allow doctors to prescribe appropriate strains of medicinal cannabis to suit patient requirements.

It is worth noting that Cann has already established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients.

Aurora Cannabis Inc (CVE:ACB), Canada’s second largest listed medicinal cannabis company, is a cornerstone investor in Cann, with a 19.9% shareholding.

View full CAN profile View Profile

Cann Group Ltd Timeline

Related Articles

x-ray
February 02 2018
A first partnership agreement was signed with a South Korean company towards the end of 2017
1518096073_biotechLatest.jpg
February 09 2018
The subsector in which Abezena is active in (monoclonal antibody and conjugated monoclonal antibodies) could expand to US$180bn, Peel Hunt’s research suggests
Antibiotics
October 04 2017
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use